The overall goal of the Population Sciences and Health Disparities Program is to conduct research to delineate and mitigate factors that affect the occurrence (or non-occurrence) of cancer in human populations and their differential manifestations in health status to ultimately reduce avoidable cancer incidence, morbidity, mortality, and to improve the quality of life for those affected by cancer (i.e. survivors and their families). Members from a variety of disciplines contribute their expertise to elucidating variabilities in cancer risk among human populations due to (A) behavioral, socio-demographic, and cultural factors;and/or (B) due to health systems factors. The Program's major research accomplishments include (1) Delineating tobacco as the key to reducing cancer through policy and practice interventions;(2) Delineating new cancer disparities across racial/ethnic and socio-demographic populations and across multiple tumor types;(3) Enhancing cancer detection, treatment, and survival through analyses of large datasets;and (4) Systematically delineating and mitigating hepatitis B viral infections as a pathway to reduce liver cancer disparities. The program has six intervention research grants focused on mitigating cancer health disparities among African Americans, American Indians, Asian Americans, and Latinos. Our P01program project, "Liver Cancer Control Interventions for Asian Americans" is the only community-based program project. We are funded as the "National Center for Reducing Asian American Cancer Health Disparities". The foundation of our research efforts are our multidisciplinary approach, our collaboration with registry epidemiologists, and our use of data from longitudinal cohort studies. The program has 24 members with affiliations to 13 different departments at UC Davis, LLNL, Kaiser Permanante, and CADHS. It has 14 NCl-funded projects for $3.5 million ADC (total peer-reviewed funding, $5.6 million ADC). The group has 322 publications for the last funding period;23% are inter-programmatic and 13% are intra-programmatic.
The Population Sciences and Health Disparities Program aims to conduct research and disseminate its findings that provide empirically-based insights that can lead to earlier cancer detection, improve the quality of life and care for cancer survivors and their families, enroll more minority patients into cancer clinical trials, and foster transdisciplinary team science approaches to reducing the cancer burden.
|Zhang, Jin; Lucchesi, Christopher; Chen, Xinbin (2016) A new function for p53 tetramerization domain in cell fate control. Cell Cycle 15:2854-2855|
|Vinall, Ruth L; Tepper, Clifford G; Ripoll, Alexandra A Z et al. (2016) Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes Cancer 7:86-97|
|Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2016) A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study. Leuk Lymphoma 57:2307-14|
|TachÃ©, VÃ©ronique; Bivina, Liga; White, Sophie et al. (2016) Lipoyltransferase 1 Gene Defect Resulting in Fatal Lactic Acidosis in Two Siblings. Case Rep Obstet Gynecol 2016:6520148|
|Lara, Joshua; Brunson, Ann; Keegan, Theresa H M et al. (2016) Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry. J Urol 196:1378-1382|
|Faisal, Farzana A; Sundi, Debasish; Tosoian, Jeffrey J et al. (2016) Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. Eur Urol 70:14-7|
|Dang, Julie H T; Chen Jr, Moon S (2016) Increasing Hepatitis B Testing and Linkage to Care of Foreign-Born Asians, Sacramento, California, 2012-2013. Public Health Rep 131 Suppl 2:119-24|
|Rowson-Hodel, Ashley R; Berg, Anastasia L; Wald, Jessica H et al. (2016) Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells. Cancer Lett 375:62-72|
|Zhao, Yong; Tu, Mei-Juan; Wang, Wei-Peng et al. (2016) Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep 6:26611|
|Monjazeb, Arta M; Kent, Michael S; Grossenbacher, Steven K et al. (2016) Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Clin Cancer Res 22:4328-40|
Showing the most recent 10 out of 608 publications